K
KOLON TISSUEGENE CO., LTD.
Kolon TissueGene, Inc., is an advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting OA of the knee. Kolon TissueGene's lead product, TG-C, is an allogeneic cell and gene therapy. The Company has plans for two pivotal Phase III clinical trials in knee OA in the U.S., the first under a Special Protocol Assessment (SPA) agreement reached with the U.S. Food and Drug Administration (FDA).
Country/Area ：South Korea
Company Email ：contact@tissuegene.com
Industry ：HealthcarePharmaceuticals
Company address ：6fl Daego B D 55 Pyeongchon Daero 2 12beon Gildongan Gu Anyang Si Gyeon Teggo Do 14067 Korea
Company website ：*****
Company phone ：(301) 921-6000
Established ：1999
Company Revenue ：$7,499,000
Number of employees ：20
SIC Code ：28283
NAICS Code ：32325
Company News
KOLON TISSUEGENE RESUMES TG-C PHASE III STUDIES IN THE U.S.
Dec 28, 2021
ROCKVILLE, Md., Dec. 28, 2021 /PRNewswire/ -- Kolon TissueGene, Inc. (KOSDAQ: 950160) (the "Company"), a leader in advanced cell and gene therapies, announced today that it has resumed patient dosing in its U.S. Phase III study of TG-C for the treatment of knee osteoarthritis (OA). The...
Dec 28, 2021
Kolon TissueGene To Expand Indications For TG-CDec 3, 2021
ROCKVILLE, Md., Dec. 3, 2021 /PRNewswire/ -- Kolon TissueGene, Inc. ("the Company"), a leader in advanced cell and gene therapies, announced today that the FDA has allowed the Company to proceed with initiation of a Phase II clinical trial in osteoarthritis (OA) of the hip. Kolon...
Dec 3, 2021Advanced Cell Therapies Market Projected to Show Strong Growth : Fujifilm, Vericel, Kolon TissueGene, Gamida CellJul 13, 2020
Edison, NJ -- (SBWIRE) -- 07/13/2020 -- A new market study is released on Covid-19 Impact on Global Advanced Cell Therapies Market with data Tables for historical and forecast years represented with Chats & Graphs spread through 90 Pages with easy to understand detailed analysis. The study highlights detailed assessment of the Market and display market sizing trend by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market developme
Jul 13, 2020Skin Replacement Market - Big Changes to Have Big Impact: Tengion, TissueGene, L'OrealJun 9, 2020
Edison, NJ -- (SBWIRE) -- 06/09/2020 -- HTF MI Analyst have added a new research study on Title Global Skin Replacement Market Report 2019 - Market Size, Share, Price, Trend and Forecast with detailed information of Product Types [Epicel & Integra etc], Applications [Chemical, Cosmetic & Pharmaceutical] & Key Players Such as Cellular Dynamics, Cynata Therapeutics, Platelet BioGenesis, Tengion, TissueGene, L'Oreal. The Study provides in-depth comprehensive analysis for regional segmen
Jun 9, 2020Kolon Tissuegene Announces Plans To Resume US Phase III Clinical Trial For TG-CApr 13, 2020
ROCKVILLE, Md., April 13, 2020 /PRNewswire/ -- Kolon TissueGene, Inc. (the "Company"), a leader in advanced cell and gene therapies, announced today that the Clinical Hold issued by the FDA in April 2019 has been lifted effective April 10, 2020, and that the Company can continue with its...
Apr 13, 2020Web Summary
Q1: What is the address of Kolon TissueGene, Inc.?
A1: Unfortunately, the provided text does not mention a specific address for Kolon TissueGene, Inc.
Q2: What products are being developed by Kolon TissueGene, Inc.?
A2: According to the text, Kolon TissueGene is developing advanced cell therapies to target various orthopedic diseases and degenerative disorders, with a focus on treating osteoarthritis of the knee using its TG-Cis technology.
Q3: In which industry does Kolon TissueGene, Inc. operate?
A3: Kolon TissueGene, Inc. operates in the biopharmaceutical industry, specifically in the area of cell and gene therapy for orthopedic diseases and degenerative disorders.
Q4: What services does Kolon TissueGene, Inc. provide?
A4: The text does not explicitly mention specific services provided by Kolon TissueGene, Inc., but it mentions that the company is developing clinical-stage advanced cell therapies and has a global manufacturing and marketing network.
Q5: How can one contact Kolon TissueGene, Inc.?
A5: According to the text, contact information for Kolon TissueGene, Inc. is not provided, but it does mention that the products discussed on its website may have different labeling in different countries.
Q6: What is the company's mission statement?
A6: The company's mission statement is to provide safe and effective therapies to patients by reducing pain and improving function associated with various orthopedic diseases and degenerative disorders.
Q7: How long has Dr. Moon J. Noh been with Kolon TissueGene, Inc.?
A7: According to the text, Dr. Moon J. Noh has been with Kolon TissueGene for over 16 years.
Q8: What is the name of the technology platform developed by Kolon TissueGene, Inc.?
A8: The name of the technology platform developed by Kolon TissueGene, Inc. is TG-C, which is designed to conveniently and effectively treat osteoarthritis of the knee by reducing pain, increasing function, and slowing the progression of the disease.
Q9: What is the expected impact of Kolon TissueGene's technology on the biopharmaceutical industry?
A9: According to the text, as time goes on, it is expected that more and more companies will rapidly move into the innovative space within drug development using cell and gene therapy technology developed by companies like Kolon TissueGene.
Q10: What is the name of the company where Dr. Seng-Ho Jeon served as CEO from 2018 to 2024?
A10: According to the text, Dr. Seng-Ho Jeon served as CEO of Daewoong Pharmaceutical from 2018 to 2024.
Q11: What is the name of the university where Dr. Young J. Kim received his Doctorate in Engineering Management?
A11: According to the text, Dr. Young J. Kim received his Doctorate in Engineering Management at George Washington University.
A1: Unfortunately, the provided text does not mention a specific address for Kolon TissueGene, Inc.
Q2: What products are being developed by Kolon TissueGene, Inc.?
A2: According to the text, Kolon TissueGene is developing advanced cell therapies to target various orthopedic diseases and degenerative disorders, with a focus on treating osteoarthritis of the knee using its TG-Cis technology.
Q3: In which industry does Kolon TissueGene, Inc. operate?
A3: Kolon TissueGene, Inc. operates in the biopharmaceutical industry, specifically in the area of cell and gene therapy for orthopedic diseases and degenerative disorders.
Q4: What services does Kolon TissueGene, Inc. provide?
A4: The text does not explicitly mention specific services provided by Kolon TissueGene, Inc., but it mentions that the company is developing clinical-stage advanced cell therapies and has a global manufacturing and marketing network.
Q5: How can one contact Kolon TissueGene, Inc.?
A5: According to the text, contact information for Kolon TissueGene, Inc. is not provided, but it does mention that the products discussed on its website may have different labeling in different countries.
Q6: What is the company's mission statement?
A6: The company's mission statement is to provide safe and effective therapies to patients by reducing pain and improving function associated with various orthopedic diseases and degenerative disorders.
Q7: How long has Dr. Moon J. Noh been with Kolon TissueGene, Inc.?
A7: According to the text, Dr. Moon J. Noh has been with Kolon TissueGene for over 16 years.
Q8: What is the name of the technology platform developed by Kolon TissueGene, Inc.?
A8: The name of the technology platform developed by Kolon TissueGene, Inc. is TG-C, which is designed to conveniently and effectively treat osteoarthritis of the knee by reducing pain, increasing function, and slowing the progression of the disease.
Q9: What is the expected impact of Kolon TissueGene's technology on the biopharmaceutical industry?
A9: According to the text, as time goes on, it is expected that more and more companies will rapidly move into the innovative space within drug development using cell and gene therapy technology developed by companies like Kolon TissueGene.
Q10: What is the name of the company where Dr. Seng-Ho Jeon served as CEO from 2018 to 2024?
A10: According to the text, Dr. Seng-Ho Jeon served as CEO of Daewoong Pharmaceutical from 2018 to 2024.
Q11: What is the name of the university where Dr. Young J. Kim received his Doctorate in Engineering Management?
A11: According to the text, Dr. Young J. Kim received his Doctorate in Engineering Management at George Washington University.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
